** Shares of Innovent Biologics Inc 1801.HK rise 3.3% to HK$31, on course to snap two consecutive session of decline

** Stock on track for the biggest one-day jump since Dec. 9, 2024; among top 10 gainers in healthcare index .HSCIH, which is up 0.8%

** Innovent says new drug application of limertinib - the third-generation epidermal growth factor receptor tyrosine kinase inhibitor, has received approval by National Medical Products Administration of China (NMPA) for treatment of lung cancer

** Hang Seng Commerce & Industry Index .HSNC and Hang Seng Index .HSI boht slip 0.1%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))